Comparison of the size distributions and immunogenicity of human papillomavirus type 16 L1 virus-like particles produced in insect and yeast cells
Authors:
- 10 April 2018
- journal article
- research article
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 41 (5) , 544-553
Abstract
Insect and yeast cells are considered the expression systems of choice for producing virus-like particles (VLPs), and numerous types of VLPs have been produced in these systems. However, previous studies were restricted to identifying the characteristics of individual VLP preparations. No direct comparison of the structures and immunogenic properties of insect and yeast-derived VLPs has so far been made. In the present study, the size distribution and immunogenic properties of human papillomavirus type 16 (HPV16) L1 VLPs produced in Spodoptera frugipedra-9 insect cells and Saccharomyces cerevisiae were compared. The insect cell-derived VLPs were larger than the yeast ones (P < 0.0001), with median sizes of 34 and 26 nm, respectively. In addition, the insect-derived VLPs appeared to be more diverse in size than the yeast-derived VLPs. Immunization of mice with 30 ng per dose of VLPs elicited 2.7- and 2.4-fold higher anti-HPV16 L1 IgG and anti-HPV16 neutralizing antibody titers than immunization with the same amounts of the yeast-derived VLPs after the 4th immunizations, respectively. Our results suggest that the choice of expression system critically affects the particle size and immunogenic property of HPV16 L1 VLPs.Keywords
Funding Information
- Korea Centers for Disease Control & Prevention (HD16A1337)
- Chung-Ang University (2017)
This publication has 30 references indexed in Scilit:
- Next generation vaccines and vectors: Designing downstream processes for recombinant protein‐based virus‐like particlesBiotechnology Journal, 2015
- The papillomavirus major capsid protein L1Virology, 2013
- Human papillomavirus and cervical cancerThe Lancet, 2013
- Insect cells as a production platform of complex virus-like particlesExpert Review of Vaccines, 2013
- Effects of downstream processing on structural integrity and immunogenicity in the manufacture of papillomavirus type 16 L1 virus-like particlesBiotechnology and Bioprocess Engineering, 2012
- Highly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastorisProtein Expression and Purification, 2011
- Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 yearsHuman Vaccines, 2009
- Therapeutic antibodies: successes, limitations and hopes for the futureBritish Journal of Pharmacology, 2009
- Identification of a Human Papillomavirus Type 16-Specific Epitope on the C-Terminal Arm of the Major Capsid Protein L1Journal of Virology, 2003
- Simian virus 40 VP1 capsid protein forms polymorphic assemblies in vitroJournal of General Virology, 2003